The prognostic significance of heart rate (HR) and its relationship with beta-blocker use are controversial and have never been evaluated in resistant hypertension.
Background
The prognostic significance of heart rate (HR) and its relationship with beta-blocker use are controversial and have never been evaluated in resistant hypertension.
Methods
In a prospective study, 528 patients with resistant hypertension had HR measured on clinical examination, electrocardiography (ECG), and during ambulatory blood pressure monitoring. Primary endpoints were a composite of fatal and nonfatal cardiovascular events, all-cause and cardiovascular mortality. Multivariable Cox regression was used to assess the associations between slow HR (< 60 bpm or < 55 bpm for nighttime HR) and fast HR (> 75 bpm or > 70 bpm for nighttime HR) and the occurrence of endpoints in relation to the reference middle HR (60-75 bpm) subgroup.
results After a median follow-up of 4.8 years, 62 patients died, 44 from cardiovascular causes; and 94 cardiovascular events occurred. Fast and slow HRs were mainly predictors of mortality, and ambulatory HRs were more significant risk markers than clinic or ECG HR. A slow 24-hour HR was a predictor of the composite endpoint (hazard ratio, 2.0; 95% confidence interval [CI], 1.2-3.4), whereas both slow and fast ambulatory HRs were predictors of cardiovascular mortality (hazard ratio, 2.3; 95% CI, 1.1-5.1). Four hundred and seventeen patients (79%) were using beta-blockers and this affected the HR prognostic value. A fast HR was a more significant risk marker in patients using beta-blockers, whereas a slow HR was a predictor mainly in those not using beta-blockers.
conclusions
There is an overall U-shaped relationship between HRs, particularly when measured during ambulatory monitoring, and prognosis in resistant hypertension. A fast HR is a significant predictor in patients using beta-blockers, while a slow heart rate is a more important predictor in those not using beta-blockers.
Keywords: beta-blocker; cardiovascular risk; heart rate; mortality; resistant hypertension. doi:10.1093/ajh/hps004 introduction A fast baseline resting heart rate (HR) has been consistently demonstrated to represent a risk marker for all-cause and cardiovascular mortality in population-based samples: [1] [2] [3] and in several cardiovascular diseases, such as acute or chronic coronary heart disease, 4, 5 and in heart failure or left ventricular dysfunction. 6 Moreover, in these 2 conditions treatment-induced HR reductions have been demonstrated to contribute to a better prognosis. 7, 8 Nevertheless, the prognostic value of fast HRs in hypertensive individuals is more controversial. This value has been demonstrated in some studies, 9, 10 but not in others, 11, 12 whereas one study 13 found a J-shaped relationship between HR and adverse outcomes. More recently, this relationship was further influenced by the so-called the "beta-blocker paradox, " 14 in which the protective cardiovascular effect of beta-blocker treatment was lower than for other antihypertensive treatments, particularly for stroke occurrence, in spite of similar blood pressure (BP) reductions. This unexpected, unfavorable effect may be attributed to beta-blockers' adverse metabolic effects, such as worsening of the lipid profile and decreased insulin sensitivity, and also to higher central BPs. 15 Furthermore, it was shown that slower HRs while on beta-blocker treatment were associated with increased risk of cardiovascular events and mortality in hypertensive patients. 16 Resistant hypertension, defined as the lack of clinic BP control despite an optimal antihypertensive treatment with at least 3 drugs including a diuretic, 17 is a rather common but understudied condition that has a very high cardiovascular risk profile. 18 As far as we know, HR has never been evaluated as a prognostic marker in individuals with resistant hypertension. Because these patients were already stable on 3 or more antihypertensive drug treatments at baseline, we were able to investigate not only the prognostic value of HR but also the influence of any HR-limiting therapy, particularly beta-blocker treatment. Therefore, we analyzed the prognostic significance of both slow and fast HRs, measured in different contexts (clinic, electrocardiography (ECG), and during ambulatory BP monitoring), for cardiovascular morbidity and mortality, as well as the influence of beta-blocker therapy on these prognostic relationships, in a large cohort of patients with resistant hypertension with up to 9 years of follow-up.
Methods

Patients and baseline procedures
This was a retrospective analysis of prospectively collected data and included 528 patients with resistant hypertension enrolled between January 1999 and December 2004 in the hypertension outpatient clinic of the University Hospital Clementino Fraga Filho. Study protocols were approved by the Research Ethics Committee of Faculty of Medicine and University Hospital, and informed consent was obtained from all participants. The enrollment criteria, baseline protocol, and diagnostic definitions have been detailed previously. [18] [19] [20] In brief, all patients referred to our clinic who fulfilled the criteria for resistant hypertension (office BP ≥ 140/90 mm Hg, using ≥ 3 antihypertensive drugs in full dosages, always including a diuretic, and considered at least moderately adherent by a validated questionnaire 21 ) were submitted to a standard protocol that included a thorough clinical examination (with particular attention to the presence of cardiovascular risk factors and target-organ damage; diagnostic definitions have been previously detailed 19, 20 ), a laboratory evaluation, a 12-lead ECG, and 24-hour ambulatory BP monitoring (ABPM). Patients with secondary hypertension were excluded from the cohort, except those with sleep apnea syndromes, which was not routinely investigated, and those with chronic parenchymal kidney diseases (only 17 patients had an estimated creatinine clearance ≤ 30 ml/min/1.73 m 2 at entry). For this analysis, 20 patients with nonsinusal rhythms on ECG were also excluded. With patients in the sitting position, office BP was measured twice by a trained physician, using a calibrated mercury sphygmomanometer and suitably sized cuffs; the BP was the mean between the 2 readings. HR was measured twice immediately before each BP measurement by radial artery palpation during 30s; the clinic HR was the mean between the 2 measurements. Electrocardiographic HR was automatically measured from standard resting 12-lead ECGs (CardioFax V electrocardiograph, Nihon-Kohden 
Follow-up and endpoints
Patients were followed up regularly until December 2007. All patients on beta-blocker treatment at baseline remained on treatment throughout the follow-up. The observation period was considered as the number of months from the first clinical evaluation to the date of the last clinical visit or the first endpoint. Thirty-five subjects (6.6%) were lost to follow-up and were considered censored observations at the date of their last hospital visit. The primary endpoints were a composite of all fatal or nonfatal cardiovascular events, all-cause and cardiovascular mortalities. Definitions of endpoints have been recently detailed. 18 In brief, cardiovascular events were as follows: fatal and nonfatal acute myocardial infarctions (AMI), sudden cardiac deaths, new-onset heart failure, death from progressive heart failure, any myocardial revascularization procedure, fatal and nonfatal strokes, any aortic or lower limb revascularization procedure, amputation above the ankle, and deaths from aortic or peripheral arterial disease. Endpoints were ascertained from medical records, death certificates, and interviews with attending physicians and patient families, using a standard questionnaire reviewed by an independent observer.
statistical analysis
Continuous data were expressed as means and SD if normally distributed or as medians and interquartile range (IQR) if asymmetrically distributed. Patients were divided into 3 subgroups according to HRs measured at the 5 contexts (clinic, ECG, 24-hour, daytime, and nighttime) as normal (between 60 and 75 bpm), slow (< 60 bpm), and fast (> 75 bpm) HRs, except for the nighttime HR, which had a 5-bpm lower cut-off value. The upper cut-off value (75 bpm) was chosen because most previous studies that demonstrated any prognostic value of fast HRs reported threshold cut-offs between 70 bpm and 90 bpm [7] [8] [9] [10] and also because it divided our patients into subgroups with sample sizes large enough to perform comprehensive statistical analyses. The lower cut-off value (60 bpm) is the traditional one used to define bradycardia. Baseline characteristics between patients with normal, slow, and fast HRs were compared by one-way analysis of variance, Kruskal-Wallis test, or χ 2 test. The assessment of the fast and slow HRs as independent predictors of the endpoints was performed by Kaplan-Meier estimation of survival curves, compared by log-rank test, and by multivariable Cox proportional hazards analysis, with the normal HR subgroup as the reference. Cox models were first adjusted for age and sex and then, for the composite endpoint, further adjusted for all potential risk factors: age, sex, smoking, physical inactivity, diabetes, dyslipidemia, previous cardiovascular diseases, serum creatinine, number of antihypertensive drugs in use, ambulatory 24-hour systolic BP, and dipping pattern. Because of the smaller number of events and to avoid overfitting, the multivariable Cox analyses for all-cause and cardiovascular mortalities were adjusted only for their significant predictors. Furthermore, all analyses were also adjusted for any HR-limiting therapy (beta-blockers, non-dihydropyridine calcium channel blockers, or clonidine), and an interaction term between HR and beta-blocker use was tested in all multivariate models and kept in the models interaction product terms with P < 0.10. Regardless of whether any interaction between the prognostic value of HR and beta-blocker use was detected, all survival analyses were repeated in patients stratified by beta-blocker use. Because of the small number of patients and consequently of endpoints in the subgroup without beta-blockers at baseline, the survival analyses in this subgroup was adjusted only for age and sex. Results were presented as hazard ratios with their 95% confidence intervals.
The proportional hazards assumption was tested and no violation was observed. Other interactions between HR subgroups and age (< 65 and ≥ 65 years), sex, and presence of diabetes and of cardiovascular disease at baseline were also examined, but none had P values < 0.10. Statistics were performed with SPSS version 19.0 package (SPSS Inc., Chicago, IL), and a 2-tailed probability value < 0.05 was considered significant.
results
Baseline characteristics and follow-up endpoints
Distributions of clinic, ECG, daytime, and 24-hour HR were similar: mean (SD) and median (IQR) were respectively 72 (12), 68 (64-80); 70 (14) , 68 (61-78); 71 (12), 69 (63-78); and 69 (11), 67 (61-76) bpm; whereas nighttime HR was slower: 63 (10), 61 (55-69) bpm. Table 1 outlines the baseline characteristics of patients with normal (60-75 bpm), slow (< 60 bpm), and fast (> 75 bpm) mean 24-hour ambulatory HR. Patients with slow HRs were older and leaner, had a lower prevalence of diabetes and lower fasting glycemia levels, and had lower diastolic BPs than patients with normal HRs. On the other hand, patients with elevated HRs were younger, were more frequently females and current smokers, had higher prevalence of diabetes and higher fasting glycemia levels, used less antihypertensive medications (mainly beta-blockers) but used more calcium channel blockers (particularly of the non-dihydropyridine class) had higher ambulatory BPs, and had higher prevalence of true (uncontrolled) resistant hypertension than patients with normal HRs. Otherwise, short-term BP variability parameters did not differ among HR subgroups. Categorization into the same subgroups by clinic or ECG HR followed similar patterns of characteristics. Overall, 417 patients (79%) were using beta-blockers at baseline, primarily (96% of them) propranolol or atenolol. None were using the new vasodilating beta-blockers.
After a median follow-up of 4.8 years (range, 1 month-9 years), 94 fatal or nonfatal cardiovascular events occurred (incidence rate: 3.9 per 100 patient-years of follow-up): 42 strokes, 21 AMIs, 14 myocardial revascularizations, 9 newonset heart failures, 4 sudden deaths, and 4 aortic or peripheral artery events. There were 62 all-cause deaths (incidence: 2.4 per 100 patient-years), 44 from cardiovascular causes (incidence: 1.7 per 100 patient-years). Patients with either fast or slow HRs had an increased incidence rate of endpoints in relation to the reference group with HRs between 60 and 75 bpm (Table 1) . Table 2 presents the results of Cox survival analyses for the association between the 5 measurements of HR and the 3 primary endpoints. In general, ambulatory HRs were more significant prognostic predictors than clinic or ECG HRs and, more important, for all-cause and cardiovascular mortalities than for the composite endpoint. Clinic HR was not a predictor of any outcome, and a slow ECG HR was a predictor only for the composite endpoint. Otherwise, fast ambulatory HRs, 24-hour, daytime, or nighttime, were significant predictors of all-cause and cardiovascular mortalities with hazard ratios ranging from 1.9 to 2.3. Slow nocturnal HR was also a predictor of all-cause mortality, and slow 24-hour HR was predictive of cardiovascular mortality and of the composite endpoint. The worse prognosis associated with both fast and slow ambulatory HRs was also demonstrated by Kaplan-Meier survival curves (Figure 1) . A blunted nocturnal HR dipping was not a predictor of any of the endpoints. Table 3 shows the prognostic value of fast and slow HRs in patients stratified by beta-blocker use at baseline. The worse prognosis associated with fast HRs was observed exclusively in patients using beta-blockers, whereas the worse prognosis of slow HRs was mainly observed in patients not using beta-blockers. The only exception was the predictive value of slow 24-hour HR for the composite endpoint, in which a significant 2-fold increased risk in patients using betablockers was found, although the risk was higher (3-fold) in the subgroup not using beta-blockers. The use of betablockers alone had no independent predictive value, neither harm nor benefit, for any of the endpoints evaluated. Short-term BP variability parameters also did not have any prognostic value and did not affect the prognostic implications of HR.
Prognostic value of fast and slow hrs and influence of beta-blocker use
discussion
As a result of this prospectively collected data study, we made three important findings. First, we observed a U-shaped relationship between HR and outcome in patients treated for resistant hypertension: both slow (< 60 bpm) and fast (> 75 bpm) HRs were significant predictors of worse prognosis, mainly for all-cause and cardiovascular mortality. Second, ambulatory HRs were more significant predictors than clinic or ECG HRs. Third, HR reduction by betablocker therapy did not appear to be harmful. However, this cannot be completely ruled out because we found a significantly increased risk of slow 24-hour HR for the composite endpoint of fatal and nonfatal cardiovascular events in patients using beta-blockers. With this exception, all other increased risks associated with slow HRs were observed in patients not using beta-blockers. Otherwise, the adverse outcomes associated with fast HRs were always observed in patients on beta-blocker treatment. Values are means (SDs) or proportions, except for triglycerides, serum creatinine, albuminuria, and number of antihypertensive drugs that are medians (interquartile ranges) and endpoints occurrence that is absolute number (incidence rate).
Abbreviations: DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure. Values are hazard ratios (95% CIs). Fast and slow heart rates were analyzed in relation to the reference group, with heart rates between 60 bpm and 75 bpm (55 bpm and 70 bpm for the nighttime period) and nondipping heart rate (nocturnal reduction < 10%) in relation to normal dipping (reduction ≥ 10%).
a For the composite endpoint, adjusted for age, sex, smoking, physical inactivity, diabetes, dyslipidemia, previous cardiovascular diseases, serum creatinine, number of antihypertensive drugs in use, ambulatory 24-hour systolic blood pressure, dipping pattern, and any rate-limiting therapy (beta-blocker, non-dihydropyridine calcium channel blocker, or clonidine).
For total mortality, adjusted for age, sex, smoking, diabetes, serum creatinine, number of antihypertensive drugs in use, dipping pattern, and any rate-limiting therapy.
For cardiovascular mortality, adjusted for age, sex, smoking, number of antihypertensive drugs in use, dipping pattern, and any rate-limiting therapy. * P < 0.05, * , * P < 0.01. CI, confidence interval; ECG, electrocardiographic. 
Total cardiovascular events
Heart Rate 60 -75 bpm Heart Rate < 60 bpm Heart Rate > 75 bpm Although the prognostic importance of fast HRs has been consistently established in population-based studies and in coronary heart disease and heart failure patients, [1] [2] [3] [4] [5] [6] [7] [8] until 2006 only 4 studies have reported on this prognostic importance in hypertensive patients. 9,10,22,23 A 2006 consensus document 24 recognized that the evidence linking HR and outcomes remained incomplete and inconsistent and advocated further research. Since that time, other studies have reported on hypertensive individuals, [11] [12] [13] [25] [26] [27] but this issue remains controversial. Some studies did not find Values are hazard ratios (95% CIs). a Multivariate Cox analyses in patients using beta-blockers were adjusted for the same covariates detailed in Table 2 . Multivariate analyses were not performed in patients not using beta-blockers because of the small number of events. * P < 0.05, * , * P < 0.01.
Abbreviations: BB, beta-blockers; CI, confidence interval; ECG, electrocardiographic. any prognostic value of baseline HR, 11, 12 although some did find a greater prognostic importance of changes in HR during follow-up than in baseline HR, 12, 13, 26 while others 11, 25 observed a prognostic influence of HR only for mortality but not for nonfatal cardiovascular events. Moreover, few studies evaluated the prognostic significance of slow HRs 13 or the influence of HR-limiting therapy. 11, 13, 27 In this regard, our results support the findings of the INVEST (International VErapamil-SR/trandolapril STudy) trial, 13 which reported a J-shaped relationship between on-treatment HR and adverse outcomes, with an increased risk of fast HRs beginning at 75 bpm and a slow HR increased risk at <60 bpm in hypertensive patients with stable coronary artery disease, without influence of the randomized treatment arm (atenolol or verapamil). It should be noted that the "baseline" HRs in our study are indeed "on-treatment" HRs because all patients were already on a stable antihypertensive treatment with at least 3 drugs and most (85%) were on rate-limiting therapy, mainly beta-blockers. Our study extended the present knowledge to patients with resistant hypertension and advanced by showing that the prognostic importance of fast HRs was predominant in patients using beta-blockers, whereas the predictive value of slow HRs seemed to be most important in patients without any rate-limiting therapy. The prognostic significance of fast HRs in patients using beta-blockers may be explained as reflecting an exaggerated sympathetic overactivity, with resistance to beta-blocker inducing HR reduction. Beyond sympathetic overactivity, other potential mechanisms linking fast HRs to cardiovascular morbidity and mortality involve progression of atherosclerotic lesions and plaque disruption due to hemodynamic shear stress, unbalanced myocardial oxygen demand and supply, ventricular arrhythmias, left ventricular dysfunction, and poor cardiorespiratory fitness. 7, 8, 28 Furthermore, patients with fast HRs at baseline had higher prevalences of cardiovascular risk factors, such as smoking, obesity, and diabetes, and higher ambulatory BPs. The use of beta-blockers in these patients may worsen the metabolic profile and increase central aortic pressure 15 and BP variability, 29 contributing to adverse prognosis. On the other hand, the physiopathological mechanisms underlying the prognostic impact of slow HRs, observed predominantly in patients without beta-blocker therapy, are unclear. Patients with baseline slow HRs were more frequently elderly males with lower body mass index and lower BPs, particularly evident in diastolic BP. These may be unspecific markers of poor health or of more advanced disease states, which may explain the association with increased mortality. Unfortunately, other markers of poor health, such as hemoglobin concentration or serum albumin, were not available in our study.
Few studies evaluated ambulatory HRs in relation to clinic or electrocardiographic HRs. In the Syst-Eur (Systolic Hypertension in Europe) trial, 10 ambulatory HR was no better than clinic HR for mortality risk stratification, while in the IDACO (International Database on Ambulatory BP Monitoring in Relation to Cardiovascular Outcomes) report, 25 clinic HR was similar to 24-hour HR regarding all-cause mortality prediction. We found that ambulatory HRs were more significant predictors of adverse prognosis than clinic or ECG HRs. This may simply reflect the greater number of readings of ambulatory monitoring in relation to clinic or ECG HR, which may more closely approach patients' usual HR. In our study, nighttime HR predicted only all-cause mortality, but daytime HR also predicted cardiovascular mortality. This is contrary to findings of the population-based Ohasama study, 30 in which both daytime and nighttime HRs were predictors only of noncardiovascular mortality. Furthermore, contrary to other studies, 25, 31 we did not observe any independent prognostic importance of the nocturnal HR dipping, although we found a trend toward an increased risk of mortality in the small group (34 patients, 7%) with a rising pattern of nighttime HR (data not shown). The reasons for these differences are not clear but may be due to different study populations.
This study has some limitations that warrant discussion. First, some potential confounders of the relationship between HR and outcomes, such as cardiorespiratory fitness and hemoglobin concentration, were not available and could not be accounted for. Second, due to the small number of patients and consequently small number of events in the subgroup of patients not using beta-blockers, a more comprehensive statistical analysis was not possible, and these results should be reviewed with caution and confirmed in larger cohorts. Moreover, the interaction analysis with betablocker use may have been affected by selection bias, because a beta-blocker was not randomly prescribed. So, it is possible that patients with fast HRs were more frequently prescribed beta-blockers than those who already had slow HRs. Therefore, the results regarding the differential prognostic significance of fast and slow HRs in relation to beta-blocker use should be considered, at most, as suggestive but not as conclusive findings and should be confirmed in other prospective studies, ideally randomized clinical trials. Third, because this study included only resistant hypertensive patients, our findings may not be generalized to less severe hypertensive populations. Otherwise, resistant hypertension is a rather common clinical condition, with an estimated prevalence of 15% to 20% of general hypertensives.
In conclusion, this prospective cohort study in a large group of resistant hypertensive patients who were followed up for up to 9 years provides evidence of a U-shaped overall relationship between HR, particularly when measured during ambulatory monitoring, and adverse outcomes. However, beta-blocker therapy may influence this association: a fast HR (> 75 bpm) is a risk predictor exclusively in patients using beta-blockers, while a slow HR (< 60 bpm) is primarily a risk marker in patients not using beta-blockers. Further studies are necessary to determine whether direct HR-limiting therapy can per se reduce adverse outcomes in hypertensives with baseline fast HRs or whether an achieved "normal" heart rate during antihypertensive treatment merely reflects an overall improved cardiovascular status, independent of any specific rate-limiting therapy. 
